Mochida Pharmaceutical will acquire the manufacturing and marketing approval of gout and hyperuricemia treatment “Uris Tablets” and related assets from Fuji Pharma Co., Ltd. for 13.5 billion yen, scheduled for execution on June 30, 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4534","jir_company_name":"Mochida Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-03-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4534-20260330-01.pdf","jir_short_summary":"Mochida Pharmaceutical will acquire the manufacturing and marketing approval of gout and hyperuricemia treatment \"Uris Tablets\" and related assets from Fuji Pharma Co., Ltd. for 13.5 billion yen, scheduled for execution on June 30, 2026.","jir_summary":"### Overview of the Acquisition\nMochida Pharmaceutical Co., Ltd. resolved at the Board of Directors meeting on March 30, 2026, to acquire the manufacturing and marketing approval of the gout and hyperuricemia treatment \"Uris Tablets\" held by Fuji Pharma Co., Ltd., along with related assets including intellectual property rights, and signed the contract on the same day. The acquisition price is 13.5 billion yen, with execution scheduled for June 30, 2026. Uris Tablets were launched in May 2020, and their sales for the fiscal year ending March 2025 were approximately 4.6 billion yen. The acquired assets will be recorded as intangible assets with no liabilities.\n\n### Outlook and Structure\nSince the acquisition execution date falls within the next consolidated fiscal year, there will be no impact on consolidated results for the fiscal year ending March 2026. The consolidated earnings forecast for the fiscal year ending March 2027 will be announced at the time of the financial results release for the fiscal year ending March 2026. Mochida Pharmaceutical will conclude a manufacturing consignment contract with Fuji Pharma, which will continue manufacturing and supply the product to Mochida Pharmaceutical. Mochida Pharmaceutical will continue sales and information provision activities as the marketing authorization holder to contribute to healthcare.","jir_financial_highlights":"Acquisition Price: 13.5 billion yen (Unknown)\nTotal Sales of the Product (Fiscal Year ending March 2025): Approximately 4.6 billion yen (Unknown)\nAcquisition Execution Date: Scheduled for June 30, 2026 (Unknown)","jir_category":"","jir_hashtags":"#MochidaPharmaceuticalCoLtd, #M&A, #UrisTablets, #ManufacturingAndMarketingApproval, #JapaneseStocks","jir_key_figures":"Acquisition Price: 13.5 billion yen\nTotal Sales of the Product (Fiscal Year ending March 2025): Approximately 4.6 billion yen\nAcquisition Execution Date: Scheduled for June 30, 2026","jir_meta_title":"Mochida Pharmaceutical to Acquire Manufacturing and Marketing Approval for Uris Tablets for 13.5 Billion Yen, Scheduled for June 2026","jir_meta_description":"Mochida Pharmaceutical will acquire the manufacturing and marketing approval and related assets for the gout and hyperuricemia treatment \"Uris Tablets\" from Fuji Pharma for 13.5 billion yen, with execution scheduled on June 30, 2026. Sales for the fiscal year ending March 2025 were approximately 4.6 billion yen.","jir_og_title":"Mochida Pharmaceutical Announces Succession of Manufacturing and Marketing Approval for Uris Tablets","jir_og_description":"Mochida Pharmaceutical will acquire the manufacturing and marketing approval and assets for \"Uris Tablets\" from Fuji Pharma, with execution scheduled in June 2026.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9404,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-37781","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n